Skip to main content Skip to section navigation Skip to footer
Careers News & Media Contact
OPKO Health, Inc. OPKO Health, Inc.
  • Therapies
    • Overview
    • Ngenla
    • Rayaldee
  • Research
    • Overview
    • Pipeline
    • Publications
    • Scientific Presentations
  • Diagnostics
  • Company
    • Overview
    • Leadership
    • Locations
  • Partnerships
  • Investors
    • Overview
    • News / Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • News & Media
  • Contact

Publications

Research

Research

  • Overview
  • Pipeline
  • Publications
  • Scientific Presentations

Publications list

Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (ERC) in non-dialysis chronic kidney disease (ND-CKD)

February 2025 | Karger

Does Correction of Secondary Hyperparathyroidism with Extended-Release Calcifediol Provide Renoprotection?

January 2025 | Karger

Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients

January 2025 | Karger

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections

June 2023 | Nature Communications

A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice

May 2022 | Science Translational Medicine

A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

February 2022 | Nature
  • Page 1
  • Page 2
  • Next Pagearrow_forward

OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, FL 33137


T: 305-575-4100
contact@opko.com

©2025 OPKO Health, Inc. All Rights Reserved.
Privacy Policy Governance Terms of use Sitemap